This story has been updated from a previous version.

NEW YORK, Jan 17 – GeneFormatics’ acquisition of Structure Function Genomics, a Princeton, NJ-based developer of tools to speed up nuclear magnetic resonance spectroscopy, is part of the company’s strategy to gain access to all three leading proteomics technologies, GeneFormatics CEO and president said Wednesday.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

A research duo estimates in PLOS One the number of papers that have used misidentified cell lines.

UK's National Institute for Health and Care Excellence approves GlaxoSmithKline's SCID gene therapy despite cost.

Science reports that Brazilian researchers are petitioning for the reversal of budget cuts.

In PLOS this week: gene flow patterns in common ash, guidelines for using morpholinos in zebrafish, and more.